Is Bolt Biotherapeutics (BOLT) overvalued? · rev $7.7M
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
This page asks whether Bolt Biotherapeutics (BOLT) looks expensive on cached numbers — not a short thesis.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
BOLT currently screens at market cap $11.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BOLT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BOLT stock page for the full model, not this heading.
Not investment advice.